Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation

The increase in the life expectancy of the population  is accompanied by an increase in the prevalence of diseases for which old and senile age are risk factors. Atrial fibrillation (AF) and chronic kidney disease (CKD) are two diseases that can coexist in a patient. The risk of ac thromboembolic an...

Full description

Bibliographic Details
Main Author: T. V. Pavlova
Format: Article
Language:English
Published: Столичная издательская компания 2022-01-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/2621
_version_ 1797232081892278272
author T. V. Pavlova
author_facet T. V. Pavlova
author_sort T. V. Pavlova
collection DOAJ
description The increase in the life expectancy of the population  is accompanied by an increase in the prevalence of diseases for which old and senile age are risk factors. Atrial fibrillation (AF) and chronic kidney disease (CKD) are two diseases that can coexist in a patient. The risk of ac thromboembolic and hemorrhagic events in this case increases due to the mutual aggravating influence of these diseases. In addition,  these patients have a high incidence of coronary  events, and cardiovascular complications are the main cause of death in patients with AF and CKD. Consequently, such patients require an integrated  approach  to treatment,  and their management is a complex  clinical task. The direct oral anticoagulant rivaroxaban has been most studied in a population  of comorbid  AF and CKD  patients and has proven a high efficacy and safety profile in these patients in randomized controlled trials. In addition,  rivaroxaban has shown  a significant  reduction in the risk of myocardial  infarction  in various patients,  as well as the possibility of preserving renal function to a greater extent compared  with warfarin therapy, and a possible positive effect on reducing  the risk of cognitive impairment.  A single dosing  regimen  can improve adherence  to treatment,  which is one of the key conditions  for achieving  the above effects. Thus, these factors make it possible to achieve comprehensive protection of comorbid  patients with AF and CKD.
first_indexed 2024-03-08T13:59:57Z
format Article
id doaj.art-451c854245d543b29ec3f69fa0a2069c
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2024-04-24T15:54:37Z
publishDate 2022-01-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-451c854245d543b29ec3f69fa0a2069c2024-04-01T07:43:41ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532022-01-0117691692610.20996/1819-6446-2021-12-081964Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial FibrillationT. V. Pavlova0Samara State Medical UniversityThe increase in the life expectancy of the population  is accompanied by an increase in the prevalence of diseases for which old and senile age are risk factors. Atrial fibrillation (AF) and chronic kidney disease (CKD) are two diseases that can coexist in a patient. The risk of ac thromboembolic and hemorrhagic events in this case increases due to the mutual aggravating influence of these diseases. In addition,  these patients have a high incidence of coronary  events, and cardiovascular complications are the main cause of death in patients with AF and CKD. Consequently, such patients require an integrated  approach  to treatment,  and their management is a complex  clinical task. The direct oral anticoagulant rivaroxaban has been most studied in a population  of comorbid  AF and CKD  patients and has proven a high efficacy and safety profile in these patients in randomized controlled trials. In addition,  rivaroxaban has shown  a significant  reduction in the risk of myocardial  infarction  in various patients,  as well as the possibility of preserving renal function to a greater extent compared  with warfarin therapy, and a possible positive effect on reducing  the risk of cognitive impairment.  A single dosing  regimen  can improve adherence  to treatment,  which is one of the key conditions  for achieving  the above effects. Thus, these factors make it possible to achieve comprehensive protection of comorbid  patients with AF and CKD.https://www.rpcardio.online/jour/article/view/2621atrial fibrillationchronic kidney diseasecomorbid conditionsanticoagulantsadherence to treatment
spellingShingle T. V. Pavlova
Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation
Рациональная фармакотерапия в кардиологии
atrial fibrillation
chronic kidney disease
comorbid conditions
anticoagulants
adherence to treatment
title Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation
title_full Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation
title_fullStr Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation
title_full_unstemmed Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation
title_short Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation
title_sort renal function protection as an important component of a comprehensive approach to the management of patients with atrial fibrillation
topic atrial fibrillation
chronic kidney disease
comorbid conditions
anticoagulants
adherence to treatment
url https://www.rpcardio.online/jour/article/view/2621
work_keys_str_mv AT tvpavlova renalfunctionprotectionasanimportantcomponentofacomprehensiveapproachtothemanagementofpatientswithatrialfibrillation